XML 169 R155.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K)
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 10 Months Ended 12 Months Ended
Dec. 13, 2019
USD ($)
Jul. 02, 2019
USD ($)
Apr. 18, 2019
USD ($)
ft²
Jul. 31, 2018
USD ($)
Sep. 30, 2018
Dec. 31, 2018
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Nov. 05, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jan. 02, 2019
USD ($)
Percentage of Total Revenue             100.00% 100.00% 100.00% 100.00%   100.00% 100.00%  
Debt instrument principal amount             $ 3,250,000   $ 3,250,000          
Lease description                 The Company has operating leases for its warehouse facility and for equipment under agreements that expire at various dates through 2023.     The Company has entered into operating leases for office and production facilities and equipment under agreements that expire at various dates through 2026.    
Operating lease liabilities           $ 3,458,000 46,000   $ 46,000     $ 3,300,000 $ 3,458,000 $ 3,458,000
Brooklyn Immunotherapeutics, LLC [Member]                            
Lease expiration term   Dec. 31, 2025                        
Rent expense   $ 485,061                        
Lease description   In connection with the Business Combination, BITX also assumed IRX’s lease for laboratory space in Brooklyn, New York (the “Laboratory Lease”), with annual rent expense for the first year of $314,577 beginning on the date of the Business Combination. Effective on July 1, 2019, the Laboratory Lease was amended to increase the space rented under the Laboratory Lease. Annual rent expense (including the Company’s pro rata share of operating expenses) for 12 months beginning July 1, 2019 increased to $485,061 pursuant to the amended Laboratory Lease, and the rent increases 3% on January 1 of each lease year. The Laboratory Lease expires on December 31, 2025.                        
Sublease payments                 32,676        
Operating lease liabilities             102,588   $ 102,588     103,350    
Brooklyn Immunotherapeutics, LLC [Member] | Successor [Member]                            
Rent expense           $ 77,170           544,214    
Sublease payments                       32,676    
Operating lease liabilities                       $ 103,350    
Brooklyn Immunotherapeutics, LLC [Member] | Predecessor [Member]                            
Rent expense                     $ 480,577      
Brooklyn Immunotherapeutics, LLC [Member] | Office Lease [Member]                            
Lease expiration term                       Nov. 30, 2026    
Rent expense                       $ 93,275    
Brooklyn Immunotherapeutics, LLC [Member] | Laboratory Lease [Member]                            
Rent expense                       $ 314,577    
Brooklyn Immunotherapeutics, LLC [Member] | Predecessor Royalty Agreements [Member]                            
Percentage of Total Revenue                     7.00%      
Brooklyn Immunotherapeutics, LLC [Member] | Collaborator Royalty Agreement [Member]                            
Percentage of Total Revenue                       6.00%    
Brooklyn Immunotherapeutics, LLC [Member] | Investor Royalty Agreement [Member]                            
Percentage of Total Revenue         4.00%       4.00%          
Royalty agreement expiration date, description         The Investor Royalty Agreement expires in September 2028.       The Investor Royalty Agreement expires in September 2028.          
Brooklyn Immunotherapeutics, LLC [Member] | CEO Separation Agreement [Member] | Chief Executive Officer [Member]                            
Severance pay $ 225,000     $ 275,000                    
Debt instrument principal amount       $ 31,731                    
Unused vacation time 37,518                          
Health and dental insurance plan $ 14,032                          
Brooklyn Immunotherapeutics, LLC [Member] | IRX Therapeutics, Inc [Member]                            
Business combination percentage                       25.00%    
Legal settlements             $ 150,000   $ 150,000     $ 100,000    
Brooklyn Immunotherapeutics, LLC [Member] | Nezu Asia Capital Management, LLC [Member] | Sublease Agreement [Member]                            
Lease expiration term     Oct. 31, 2026                      
Area of land | ft²     999                      
Lease term     8 years                      
Sublease payments     $ 78,422                      
Increase in rent expense     2.25%